876 related articles for article (PubMed ID: 22208980)
1. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
2. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule.
Jakob CG; Edalji R; Judge RA; DiGiammarino E; Li Y; Gu J; Ghayur T
MAbs; 2013; 5(3):358-63. PubMed ID: 23549062
[TBL] [Abstract][Full Text] [Related]
3. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
4. Design and generation of DVD-Ig™ molecules for dual-specific targeting.
DiGiammarino E; Ghayur T; Liu J
Methods Mol Biol; 2012; 899():145-56. PubMed ID: 22735951
[TBL] [Abstract][Full Text] [Related]
5. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.
Wu C; Ying H; Grinnell C; Bryant S; Miller R; Clabbers A; Bose S; McCarthy D; Zhu RR; Santora L; Davis-Taber R; Kunes Y; Fung E; Schwartz A; Sakorafas P; Gu J; Tarcsa E; Murtaza A; Ghayur T
Nat Biotechnol; 2007 Nov; 25(11):1290-7. PubMed ID: 17934452
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
8. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
9. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen.
Correia I; Sung J; Burton R; Jakob CG; Carragher B; Ghayur T; Radziejewski C
MAbs; 2013; 5(3):364-72. PubMed ID: 23572180
[TBL] [Abstract][Full Text] [Related]
10. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
11. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
13. Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting.
Gong S; Wu C
Methods; 2019 Feb; 154():87-92. PubMed ID: 30081078
[TBL] [Abstract][Full Text] [Related]
14. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
15. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
16. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
[TBL] [Abstract][Full Text] [Related]
17. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of semi-homogeneous assay formats for dual-specificity antibodies.
Jiang G; Lee CW; Wong PY; Gazzano-Santoro H
J Immunol Methods; 2013 Jan; 387(1-2):51-6. PubMed ID: 23063556
[TBL] [Abstract][Full Text] [Related]
19. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
20. [Bispecific antibodies: what future?].
Pèlegrin A; Robert B
Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
